Biophytis S.A. Asset Resilience Ratio
Biophytis S.A. asset resilience ratio. Biophytis S.A. (ALBPS) has an Asset Resilience Ratio of 16.07% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Biophytis S.A. (ALBPS) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Biophytis S.A. (2012–2024)
Asset resilience ratio of Biophytis S.A. from 2012 to 2024. This chart shows how Biophytis S.A.'s Asset Resilience Ratio has changed over time. Read Biophytis S.A. total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Biophytis S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Biophytis S.A. (ALBPS) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €850.00K | 12.83% |
| Short-term Investments | €214.00K | 3.23% |
| Total Liquid Assets | €1.06 Million | 16.07% |
Asset Resilience Insights
- Good Liquidity Position: Biophytis S.A. maintains a healthy 16.07% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Biophytis S.A. Industry Peers by Asset Resilience Ratio
Compare Biophytis S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Biophytis S.A. Asset Resilience Ratio by Year (2012–2024)
Biophytis S.A. asset resilience ratio by year from 2012 to 2024. The table below shows the annual Asset Resilience Ratio data for Biophytis S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.75% | €190.00K ≈ $222.13K |
€6.90 Million ≈ $8.07 Million |
-22.98pp |
| 2023-12-31 | 25.74% | €3.08 Million ≈ $3.60 Million |
€11.96 Million ≈ $13.98 Million |
+0.34pp |
| 2022-12-31 | 25.39% | €5.58 Million ≈ $6.53 Million |
€21.99 Million ≈ $25.71 Million |
+2.70pp |
| 2021-12-31 | 22.69% | €8.23 Million ≈ $9.62 Million |
€36.26 Million ≈ $42.39 Million |
-32.43pp |
| 2020-12-31 | 55.13% | €15.00 Million ≈ $17.54 Million |
€27.21 Million ≈ $31.81 Million |
+52.44pp |
| 2019-12-31 | 2.69% | €475.00K ≈ $555.32K |
€17.67 Million ≈ $20.66 Million |
-43.05pp |
| 2018-12-31 | 45.74% | €10.00 Million ≈ $11.69 Million |
€21.86 Million ≈ $25.56 Million |
+9.21pp |
| 2016-12-31 | 36.53% | €3.07 Million ≈ $3.58 Million |
€8.39 Million ≈ $9.81 Million |
+36.53pp |
| 2015-12-31 | 0.00% | €367.00 ≈ $429.06 |
€13.52 Million ≈ $15.80 Million |
-24.83pp |
| 2012-12-31 | 24.84% | €300.49K ≈ $351.31K |
€1.21 Million ≈ $1.41 Million |
-- |
About Biophytis S.A.
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement w… Read more